Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.

Experts explain how differentiating these subtypes guides treatment choices and outcomes.

The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

The panel addresses common patient frustrations and therapeutic limitations in today’s dry eye landscape.

Experts highlight management nuances in patients with neuropathic pain, post–refractive surgery complications, or contact lens intolerance.

Panelists discuss new DED treatments like Miebo and Vevye and how they integrate into treatment algorithms.

The team reviews acoltremon’s mechanism in promoting basal tear production and maintaining ocular surface health.

They evaluate key efficacy data and patient outcomes from the COMET-2 and COMET-3 clinical trials.

The importance of combining clinical metrics and patient-reported outcomes is examined.

Strategies for tapering and sustaining therapy once stabilization is achieved are discussed.

The series concludes with guidance on adopting emerging therapies, managing patient expectations, and addressing unmet needs in dry eye care.